DyslipidemiasPARTAGE-DNCT07543718
Group Medical Visits for Patients With Dyslipidemia
A study testing Group medical visits in people with Dyslipidemias, run by Université de Sherbrooke at 1 site in Canada.
Trial summary
Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Dyslipidemias
- What is being tested?
- Group medical visits
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 288 participants
- Where
- 1 siteCanada
- Study dates
- Apr 2026to Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol/L or non-HDL-C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L
Who cannot join
- Patients unable to participate in GMV sessions or to provide informed consent
- Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months)
- A diagnosis of terminal illness or a life expectancy of less than 12 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Unité de médecine familiale du Grand-Moncton
Dieppe, New Brunswick, E1A1G6
Mathieu Belanger, PhD, 5068632221, mathieu.f.belanger@usherbrooke.ca
About this study
Official title: Improving Care Through Group Medical Visits for Patients With Dyslipidemia
Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.
Read the detailed description
The healthcare system is in crisis. On one hand, the population requires more healthcare services due to aging and the increasing prevalence of chronic diseases. On the other hand, proportionally fewer healthcare professionals are available to meet the demand. Ample evidence suggests that strengthening the primary healthcare system could improve the population's health, particularly among individuals with chronic diseases, including cardiovascular diseases. The introduction of group medical visits (GMVs) is one proposed innovation to revitalize primary healthcare. GMVs are a type of medical appointment offered to a group of patients with similar medical conditions, replacing the traditional one-on-one consultation format. During a GMV, patients can receive a health assessment, education about their condition, including the prevention of complications, as well as prescriptions, lab test requests, or referrals to other healthcare professionals. GMVs have been integrated into primary healthcare systems in other countries (primarily to promote healthy lifestyle modifications) and are associated with clinically significant improvements in patient behaviors and health outcomes. Other studies have also shown that GMVs improve access to primary healthcare, reduce emergency department visits, and enhance quality of life, self-efficacy, and patient satisfaction with care. However, most studies assessing the effectiveness of GMVs focused on patients with diabetes, meaning there is little information on the impact of GMVs on patients with other conditions predisposing to cardiovascular diseases. However, several barriers to implementing GMVs have been identified, including uncertainty about remuneration for the intervention. The government of New Brunswick recently approved a billing code allowing family physicians to be compensated for providing GMVs to patients with specific conditions, including dyslipidemia - which is at the origin of most cases of cardiovascular diseases, and which can be effectively managed with lifestyle interventions. Nevertheless, this code has seen little to no use due to uncertainty surrounding how best to implement GMVs. The main objective is to assess the implementation of GMVs for patients with dyslipidemia in a NB-based primary healthcare clinic serving over 15,000 patients. This is meant to prepare the ground for a large trial.
It is estimated that >4,000 patients at the study clinic have dyslipidemia. A new series of VMGs will be launched every 3-6 months and 20 patients with dyslipidemia will be invited for each series. Simultaneously with the implementation of GMVs, a data collection process will take place to evaluate the quality of implementation using the RE-AIM framework. Through this process, Reach will be represented by the proportion of invited patients who participate in GMVs. Additionally, sociodemographic data from the clinics' electronic medical record (EMR) system will be used to assess whether participating patients are representative of all eligible patients. Effectiveness will be assessed by administering pre- and post-GMV questionnaires to measure changes in patient knowledge, self-efficacy, behavioral change intentions, and actual behaviors (using surveys from the Canadian Health Measures Survey by Statistics Canada). Effectiveness will also be assessed by comparing the clinical outcomes (i.e., lipids, hospitalisation for cardiovascular conditions) of the patients recruited with those of matched controls identified through the EMR. Adoption will be assessed as the proportion of eligible patients invited to GMVs by their primary care providers. Implementation will be evaluated through a modified interactive assessment grid to evaluate which key elements of the initiative were delivered as planned. All challenges encountered and any adaptations made to the implementation plan will also be considered as part of the implementation assessement. Maintenance: physicians and clinic managers will be surveyed about their willingness to continue offering GMVs for patients with dyslipidemia. Additionally, the number of GMVs delivered through every six month period will be monitored to track variations in service delivery.
- Conditions
- Dyslipidemias
- Being tested
- Group medical visits
- Medical subject headings
- Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group medical visitsBehavioural
Group medical visits are designed to improve knowledge of participants and promote self-management.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | The intervention consists of regular care supplemented by a series of group medical visits (GMVs). Each series of GMVs will last 9-12 months and will include eight sessions of 90-120 minutes covering topics related to lifestyle medicine within the context of dyslipidemia management. These sessions will be offered to groups of 8 to 12 patients and delivered by a mix of family physicians, dietitians, kinesiologists, and psychologists, all trained to deliver GMVs. Each session will begin with a revision of the goals established in the previous session, followed by a didactic component including demonstrations, questioning, and experiential activities. Emphasis will be placed on health self management and on developing realistic, specific, and observable personal goals. The sessions will include opportunities for social interaction among participants and will offer opportunities for brief one on one consultations patients and health professionals if needed. Receives: Behavioral: Group medical visits |
| Usual care group | No intervention | Participants in the usual-care group will have access to their regular follow-up with their primary care providers. They will also have the option to take part in the GMVs after the project's final evaluation period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lipid profile
Low-Density Lipoprotein; High-Density Lipoprotein; Total cholesterol; Triglycerides
Measured: 12 months
Secondary outcomes (12)
Recruitment proportion
Proportion of patients invited to participate in GMVs who actually take part;
Measured: 12 months
Representativeness of eligible patients
Comparision of sociodemographic data among patients recruited and those representative of the target population
Measured: 12 months
Attitudes of health professionals towards GMVs
Health professionnals perceptions related to GMVs and to their ability to deliver GMVs. This is assessed through 10 items asking professionals to rate their level of confidence on a 0 to 100% scale raled to their: motivation to recommend GMVs; likelihood to recommend; confidence in discussing it with patients; confidence it will improve patients' knowledge; confidence it will provide appropriate care; confidence it will improve behaviours; confidence it will improve lipid profile; confidence it will improve primary care access; confidence it will reduce needs for individual appointments; confidence it will reduce risk of developing complications.
Measured: 12 months
Frequency of access to healthcare
Patients patterns of primary care and emergency health service utilization will be described using data from electronic medical records. This will be summarized as the number of individual primary care and emergency visits per year.
Measured: 12 months
Patients' self-efficacy
Patient sense of self-efficacy; confidence in their ability to manage their health condition.
Measured: 12 months
Patients' stage of behaviour change
Self reported stage of behaviour change in accordance with Prochaska and DiClemente's Transtheoretical Model. One question asks participants to identify their stage of change regarding their eating habits and one question asks participants to identify their stage of change regarding their exercise habits.
Measured: 12 months
Patients' physical activity level
Physical activity is assessed with the short form (7 questions) of the International Physical Activity Questionnaire (IPAQ)
Measured: 12 months
Patients' eating habits
Eating behaviours are assessed with the Mini-EAT (Eating Assessment Tool), which is a 9 item questionnaire that assesses frequency of consumption of: fruits, vegetables, legumes, fish, whole grains, regined grains, low-fat dairy, high-fat dairy, and sweets.
Measured: 12 months
Proportion invited
Proportion of eligible patients invited to participate in GMVs who receive such an invitation from their primary care providers
Measured: 24 months
Offer of GMVs
Proportion of primary care providers who offer their patients to participate in GMVs.
Measured: 24 months
Implementation fidelity
Description of whether the intervention components were delivered as planned and of adjustments made to address challenges encountered.
Measured: 24 months
Plans to maintain GMVs
Description of intentions to continue offering GMVs along with description of the infrastructure and resources dedicated to sustain the delivery of GMVs. This documents steps taken to incorporate the intervention into core organisational standard practices rather than treating it as a temporary project, if applicable.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study startApr 2026 (estimated)
- Primary completionJan 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DyslipidemiasStudies of the same condition, open and under way.
- More trials run by Université de SherbrookeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 288 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université de Sherbrooke
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07543718
- Sponsor's protocol ID
- CIHR550827
- Acronym
- PARTAGE-D
- Status last verified
- Mar 2026
- First submitted
- 27 Mar 2026
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Once the study is completed, the data will be available through data sharing agreements.
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Care Through Group Medical Visits for Patients With Dyslipidemia
- ClinicalTrials.gov ID
- NCT07543718
- Acronym / sponsor ID
- PARTAGE-D / CIHR550827
- Conditions
- Dyslipidemias
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 288 participants (estimated)
- Lead sponsor
- Université de SherbrookeUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- Jan 2030 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 22 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.
Detailed description
The healthcare system is in crisis. On one hand, the population requires more healthcare services due to aging and the increasing prevalence of chronic diseases. On the other hand, proportionally fewer healthcare professionals are available to meet the demand. Ample evidence suggests that strengthening the primary healthcare system could improve the population's health, particularly among individuals with chronic diseases, including cardiovascular diseases. The introduction of group medical visits (GMVs) is one proposed innovation to revitalize primary healthcare. GMVs are a type of medical appointment offered to a group of patients with similar medical conditions, replacing the traditional one-on-one consultation format. During a GMV, patients can receive a health assessment, education about their condition, including the prevention of complications, as well as prescriptions, lab test requests, or referrals to other healthcare professionals. GMVs have been integrated into primary healthcare systems in other countries (primarily to promote healthy lifestyle modifications) and are associated with clinically significant improvements in patient behaviors and health outcomes. Other studies have also shown that GMVs improve access to primary healthcare, reduce emergency department visits, and enhance quality of life, self-efficacy, and patient satisfaction with care. However, most studies assessing the effectiveness of GMVs focused on patients with diabetes, meaning there is little information on the impact of GMVs on patients with other conditions predisposing to cardiovascular diseases. However, several barriers to implementing GMVs have been identified, including uncertainty about remuneration for the intervention. The government of New Brunswick recently approved a billing code allowing family physicians to be compensated for providing GMVs to patients with specific conditions, including dyslipidemia - which is at the origin of most cases of cardiovascular diseases, and which can be effectively managed with lifestyle interventions. Nevertheless, this code has seen little to no use due to uncertainty surrounding how best to implement GMVs. The main objective is to assess the implementation of GMVs for patients with dyslipidemia in a NB-based primary healthcare clinic serving over 15,000 patients. This is meant to prepare the ground for a large trial.
It is estimated that >4,000 patients at the study clinic have dyslipidemia. A new series of VMGs will be launched every 3-6 months and 20 patients with dyslipidemia will be invited for each series. Simultaneously with the implementation of GMVs, a data collection process will take place to evaluate the quality of implementation using the RE-AIM framework. Through this process, Reach will be represented by the proportion of invited patients who participate in GMVs. Additionally, sociodemographic data from the clinics' electronic medical record (EMR) system will be used to assess whether participating patients are representative of all eligible patients. Effectiveness will be assessed by administering pre- and post-GMV questionnaires to measure changes in patient knowledge, self-efficacy, behavioral change intentions, and actual behaviors (using surveys from the Canadian Health Measures Survey by Statistics Canada). Effectiveness will also be assessed by comparing the clinical outcomes (i.e., lipids, hospitalisation for cardiovascular conditions) of the patients recruited with those of matched controls identified through the EMR. Adoption will be assessed as the proportion of eligible patients invited to GMVs by their primary care providers. Implementation will be evaluated through a modified interactive assessment grid to evaluate which key elements of the initiative were delivered as planned. All challenges encountered and any adaptations made to the implementation plan will also be considered as part of the implementation assessement. Maintenance: physicians and clinic managers will be surveyed about their willingness to continue offering GMVs for patients with dyslipidemia. Additionally, the number of GMVs delivered through every six month period will be monitored to track variations in service delivery.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Behavioral: Group medical visitsThe intervention consists of regular care supplemented by a series of group medical visits (GMVs). Each series of GMVs will last 9-12 months and will include eight sessions of 90-120 minutes covering topics related to lifestyle medicine within the context of dyslipidemia management. These sessions will be offered to groups of 8 to 12 patients and delivered by a mix of family physicians, dietitians, kinesiologists, and psychologists, all trained to deliver GMVs. Each session will begin with a revision of the goals established in the previous session, followed by a didactic component including demonstrations, questioning, and experiential activities. Emphasis will be placed on health self management and on developing realistic, specific, and observable personal goals. The sessions will include opportunities for social interaction among participants and will offer opportunities for brief one on one consultations patients and health professionals if needed. |
| Usual care group | No intervention | –Participants in the usual-care group will have access to their regular follow-up with their primary care providers. They will also have the option to take part in the GMVs after the project's final evaluation period. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol/L or non-HDL-C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L
Key exclusion criteria (3 listed)
- Patients unable to participate in GMV sessions or to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group medical visitsGroup medical visits are designed to improve knowledge of participants and promote self-management. | Behavioural | Intervention group |
Primary outcome
Lipid profile
Time frame: 12 months
Low-Density Lipoprotein; High-Density Lipoprotein; Total cholesterol; Triglycerides
12 secondary outcomes
Recruitment proportion
Time frame: 12 months
Representativeness of eligible patients
Time frame: 12 months
Attitudes of health professionals towards GMVs
Time frame: 12 months
Frequency of access to healthcare
Time frame: 12 months
Patients' self-efficacy
Time frame: 12 months
Patients' stage of behaviour change
Time frame: 12 months
Patients' physical activity level
Time frame: 12 months
Patients' eating habits
Time frame: 12 months
Proportion invited
Time frame: 24 months
Offer of GMVs
Time frame: 24 months
Implementation fidelity
Time frame: 24 months
Plans to maintain GMVs
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Individual participant dataSharing planned: Yes. Once the study is completed, the data will be available through data sharing agreements.
Related trials for Dyslipidemias
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group medical visits in people with Dyslipidemias, run by Université de Sherbrooke at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mathieu Belanger, PhD (5068632221, mathieu.f.belanger@usherbrooke.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lipid profile (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.